Skip to main content
Clinical Trials/NCT04161859
NCT04161859
Completed
Not Applicable

Observational Study on the Use of the Nutraceutical With Cardio-metabolic Actions in the Patient in Primary and Secondary Prevention

University of Pavia1 site in 1 country387 target enrollmentMay 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dyslipidemias
Sponsor
University of Pavia
Enrollment
387
Locations
1
Primary Endpoint
Prevalence of the use of nutraceutical in clinical practice
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages.

Detailed Description

The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages. In particular, attention will be focused on the following substances: berberine (500-1000 mg/day), monacolin (5-10 mg/day), phytosterols (0.9-1.8 g/day), resveratrol (100-500 mg/day), omega-3 (1-3 g/day), alpha lipoic acid (400-800 mg/day), curcumin (400 mg/day), psyllum (3.5 g/day), coenzyme Q10 (100-200 mg/day), inositol (250-600 mg/day), glucomannan (1-4 g/day), chitosan (800-1200 mg/day), guar fiber (10-20 g/day), L-arginine (250 mg/day).

Registry
clinicaltrials.gov
Start Date
May 1, 2017
End Date
March 1, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Giuseppe Derosa

Principal Investigator

University of Pavia

Eligibility Criteria

Inclusion Criteria

  • Diabetic patients in primary and secondary prevention or Hypertensive patients in primary and secondary prevention or Dyslipidemic patients in primary and secondary prevention

Exclusion Criteria

  • Patients with hystory of malignancy, and significant neurological or psychiatric disturbances, including alcohol or drug abuse.

Outcomes

Primary Outcomes

Prevalence of the use of nutraceutical in clinical practice

Time Frame: From 2010 to 2015

Prevalence

Study Sites (1)

Loading locations...

Similar Trials